- Home
- AVTX vs ALEC Comparison
AVTX vs ALEC Comparison
Compare AVTX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | ALEC |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 204.1M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AVTX | ALEC |
|---|---|---|
| Price | $14.22 | $1.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $34.50 | $3.33 |
| AVG Volume (30 Days) | 387.9K | ★ 868.8K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $192,000.00 | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $3.39 | $0.87 |
| 52 Week High | $20.72 | $3.40 |
Technical Indicators
Market Signals| Indicator | AVTX | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 52.02 |
| Support Level | $13.50 | $1.86 |
| Resistance Level | $14.81 | $2.00 |
| Average True Range (ATR) | 1.12 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 32.45 | 40.98 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.